Clinical trials: Normal Control
Allergic Conjunctivitis
Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers
The purpose of this study is to evaluate the safety of a novel contact lens in healthy normal volunteers
- Trial name
- NCT00569777
- Testing
- K-Lens (generic name not established) and Ketotifen
- Where
- 3 sites in United States
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Vistakon Pharmaceuticals
Venous Leg Ulcer, Venous Stasis
SkinTE® in the Treatment of Venous Leg Wounds
This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on a commercially available human autologous homologous skin construct with SOC dressing compared to SOC dressings…
- Conditions
- Venous Leg Ulcer, Venous Stasis, Venous Stasis Ulcer
- Trial name
- NCT03881267
- Testing
- Human Autologous Homologous Skin Construct, Additional Outer Dressing Application, Fibracol Wound Dressing
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- PolarityTE
Soft Tissue Anesthesia (Numbness)
Safety and Efficacy Study of NV-101 in Dental Patients
The purpose of this study was: to determine if NV-101 accelerates recovery from numbness compared to placebo to evaluate safety of NV-101
- Trial name
- NCT00154167
- Testing
- NV-101 (phentolamine mesylate solution)
- Where
- United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Novalar Pharmaceuticals, Inc.
Ventral Hernia
Hernia Repair in Multiply Morbid Patients
Support of a ventral hernia repair with a prosthetic mesh has been demonstrated to result in a diminished rate of hernia recurrence.
- Trial name
- RAM2P (NCT00930787)
- Testing
- Strattice Reconstructive Tissue Matrix (Hernia Repair), Proceed Surgical Mesh (Hernia repair)
- Where
- 13 sites in United States
- Volunteers
- 23 people
- Sponsor
- LifeCell
Arthritis, Rheumatoid
A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis
The purpose of this study is to evaluate the efficacy and safety of nipocalimab versus placebo in participants with moderate to severe active rheumatoid arthritis (RA).
- Trial name
- NCT04991753
- Testing
- Nipocalimab
- Where
- 28 sites in United States, Germany and 3 more
- Volunteers
- 53 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin.
- Trial name
- OptIMMize-1 (NCT04435600)
- Testing
- Risankizumab, Ustekinumab
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 139 people
- Sponsor
- AbbVie
Generalized Pustular Psoriasis
Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis
To evaluate efficacy, safety, and tolerability of spesolimab (BI 655130) compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.
- Trial name
- NCT03782792
- Testing
- Spesolimab
- Where
- 37 sites in United States, China and 10 more
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Necrotizing Soft Tissue Infections, Necrotizing Fasciitis
Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections
The purpose of this study is to determine whether AB103 is safe and effective in the treatment of patients with necrotizing soft tissue infections (NSTI) receiving standard of care therapy.
- Conditions
- Necrotizing Soft Tissue Infections, Necrotizing Fasciitis, Fournier's Gangrene
- Trial name
- ACCUTE (NCT02469857)
- Testing
- AB103 0.5 mg/kg, NaCl 0.9%
- Where
- 71 sites in United States, France
- Volunteers
- 290 people
- Sponsor
- Atox Bio Ltd
Glioblastoma, Gliosarcoma
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
This phase II clinical trial studies how well ERC1671 plus Granulocyte-macrophage colony-stimulating factor (GM-CSF) plus Cyclophosphamide with Bevacizumab works compared to Placebo Injection plus Placebo Pill with Bevacizumab in…
- Trial name
- NCT01903330
- Testing
- ERC1671, GM-CSF, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 84 people
- Sponsor
- Epitopoietic Research Corporation
Psoriasis
Exploratory Study to Investigate Efficacy of LAS41004 in a Psoriasis Plaque Test
The aim of the exploratory study is to compare the dose-related efficacy of LAS41004 in a Psoriasis Plaque Test (PPT).
- Trial name
- NCT01360944
- Testing
- LAS41004, reference
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- Almirall, S.A.
Arthritis, Rheumatoid
A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects
This study is to evaluate the efficacy and safety of ASP015K monotherapy and to evaluate the dose-dependent response of ASP015K in moderate to severe Rheumatoid Arthritis (RA) subjects given ASP015K for 12 weeks.
- Trial name
- NCT01649999
- Testing
- peficitinib
- Where
- 7 sites in Japan
- Volunteers
- 281 people
- Sponsor
- Astellas Pharma Inc
Wrinkle, Lax Skin
A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment
A prospective, 180-day, randomized, multicenter, independent blinded evaluators, controlled study of treatment with the Thermage FLX System
- Conditions
- Wrinkle, Lax Skin, Lines Skin
- Trial name
- NCT07187297
- Testing
- Thermage FLX
- Where
- 7 sites in United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Actinic Keratosis
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
This trial will be conducted to explore the biological effects in the skin following treatment with PEP005 Gel, 0.05% administered for two consecutive days, assessed by reflectance confocal microscopy.
- Trial name
- NCT01449513
- Testing
- Ingenol mebutate
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Rosacea
M89PF in Rosacea Associated With Erythema and Sensitive Skin
Rosacea is a common facial dermatosis, with flares induced by exposome factors. M89PF containing Vichy mineralizing water, probiotic fractions, hyaluronic acid, niacinamide and tocopherol repairs the skin barrier and reinforces…
- Trial name
- NCT05562661
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
- Trial name
- TRuE-PN2 (NCT05764161)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 76 sites in United States, Australia and 11 more
- Volunteers
- 190 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
This is a Randomized, Double-blind, Vehicle-Controlled, Seamless and Adaptive-designed Phase II/III Study to Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Adult Patients with Mild-to-Moderate Atopic Dermatitis.
- Trial name
- MARBLE-23 (NCT04717310)
- Testing
- SHR0302 Ointment, Vehicle
- Where
- 31 sites in China
- Volunteers
- 645 people
- Sponsor
- Reistone Biopharma Company Limited
Cutaneous Lichen Planus
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
This study will evaluate the safety and efficacy of GIA632 in participants with moderate to severe cutaneous lichen planus (cLP).
- Trial name
- ELIPSI (NCT07775924)
- Testing
- GIA632
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 259 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate
Primary Objective: To demonstrate the treatment effect of sarilumab and methotrexate (MTX) compared to etanercept and MTX in participants with rheumatoid arthritis (RA) and an inadequate response to adalimumab and MTX by…
- Trial name
- RA-COMPARE (NCT01764997)
- Testing
- Sarilumab, Etanercept, Methotrexate
- Where
- 257 sites in United States, Argentina and 29 more
- Volunteers
- 776 people
- Sponsor
- Sanofi
Chronic Idiopathic Urticaria
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
The study is a Phase II, dose-ranging, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of a single subcutaneously administered omalizumab dose as add-on therapy for the…
- Trial name
- NCT00866788
- Testing
- omalizumab, H1 antihistamines, Diphenhydramine
- Volunteers
- 90 people
- Sponsor
- Genentech, Inc.
Atopic Dermatitis
A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis
This is a Phase 1b, 2-week study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of SB414 in subjects with mild to moderate AD.
- Trial name
- NCT03431610
- Testing
- SB414 2%, SB414 6%, Vehicle
- Where
- 9 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Novan, Inc.